Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Cancer remains a leading global cause of death, with immunotherapies offering new treatment avenues.
• Current cancer immunotherapies face limitations, especially for cancers with few mutated antigens.
• Adenoviral vectors are utilized in various treatments but have shown limited success in cancer therapy.

Purpose of the Study:

• To review the therapeutic potential of adenoviral vectors in cancer treatment.
• To explore the application of adenoviral vectors in targeting endogenous retroviruses (ERVs) for cancer therapy.
• To discuss virus-like-vaccine (VLV) technology for eliciting immune responses against ERVs in cancer.

Main Methods:

• Review of current literature on adenoviral vectors, cancer immunotherapy, and endogenous retroviruses.
• Examination of ERVs as potential cancer targets due to their presence in tumors and absence in healthy tissues.
• Discussion of virus-like-vaccine (VLV) technology, integrating adenoviral vectors and virus-like particles (VLPs).

Main Results:

• Endogenous retroviruses (ERVs) constitute a significant portion of the human genome and are implicated in various cancers.
• ERVs possess low immunogenicity and immunosuppressive properties, aiding cancer cells in evading immune surveillance.
• Virus-like-vaccine (VLV) technology offers a strategy to target ERVs, potentially stimulating robust B-cell, CD8+, and CD4+ T-cell responses.

Conclusions:

• Adenoviral vectors hold potential as therapeutic tools for cancer, particularly when engineered to target ERVs.
• Targeting ERVs presents a promising strategy for developing effective cancer immunotherapies, especially for tumors with limited neoantigens.
• Virus-like-vaccine (VLV) technology combining adenoviral vectors and VLPs could be instrumental in overcoming ERV-mediated immune suppression and enhancing anti-cancer immunity.